Dr Côme Bommier reflects on the influences that shaped his career, the evolving landscape of lymphoma treatment and the central role of patients in clinical decision-making. With a clear vision for more personalised and lasting care, he offers thoughtful insight into the challenges and responsibilities of modern haematology.
Dr. David Porter, President of ASTCT, outlines his vision for the Society’s future, emphasizing expanded access to cell therapies, multidisciplinary collaboration, and a bold strategic plan through 2030. He highlights exciting advances in treating autoimmune diseases and solid tumors, positioning ASTCT to lead in a rapidly evolving therapeutic landscape.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dr Zachary Frosch, Fox Chase Cancer Center, shares how patient priorities guide his clinical decisions and how his research stems from real-world challenges. He also reflects on key lessons from mentorship and the ongoing dialogue between the clinic and the research lab that shapes his work.
The 30th EHA Congress will take place in Milan from 12–15th June 2025 and touchHAEMATOLOGY are thrilled to be attending on site, speaking with leading experts across the field. Keep an eye out on our website and social media for the latest news, updates and Q&As fresh from Milan!
Dr. Esra Gülderen discusses her path into hematology, the critical role of mentorship, and how early research experiences shaped her confidence. Now a Co-chair of the EBMT Trainee Committee, she shares what motivates her and why clear communication, curiosity, and resilience are essential traits for aspiring haematologists.
In this interview, Dr Elena Crisà (Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy) shares her insights into the most fulfilling aspects of practicing haematology, from working in cutting-edge new treatment options in clinical trials to guiding patients through complex treatment decisions.
Protagonist Therapeutics Inc. and Takeda have shared positive topline findings from the phase III VERIFY trial (NCT05210790), which investigated rusfertide in patients with polycythemia vera (PV) who require frequent phlebotomies. Participants were randomly assigned to receive either rusfertide or a ...
CD7-targeted CAR T-cell therapy, WU-CART-007, demonstrates encouraging anti-leukemic activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL). This updated analysis from the phase II portion ...
A chemotherapy-free approach combining ibrutinib-rituximab (IR) has outperformed standard chemotherapy regimens in treating older patients with newly-diagnosed mantle cell lymphoma (MCL), according to findings from the ENRICH trial presented at the 66th American Society of Hematology Annual Meeting. The study ...
The American Society of Hematology (ASH) held its 66th Annual Meeting from 7–10 December 2024. Among the highlights of the meeting were six late-breaking abstracts that have the potential to influence how healthcare professionals approach a range of condition,s from introducing ...
The IMpactMF trial is a phase 1/1b study evaluating the addition of Imetelstat to ruxolitinib for myelofibrosis patients who show an inadequate response to ruxolitinib alone. By combining these therapies earlier in treatment, the study aims to assess safety, tolerability ...
As 2024 draws to a close, we’re celebrating a great year of content. From insightful expert Q&As and news articles to conference highlights and a wealth of medical education, it’s been a year filled with content that we hope has been useful to our audience. We’ve had the privilege of connecting with leading experts and working alongside medical societies to support the haematology community with high-quality, easily accessible content.
The 66th ASH Annual Meeting and Exposition 2024 in San Diego saw approximately 30,000 visitors, 8,000 abstracts and 275 exhibitors. With so much exciting new data and scientific breakthroughs presented, touchHAEMATOLOGY is excited to break this down and bring you some of the highlights. ...
This interview features Dr Nico Gagelmann (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) and Dr Claire Horgan (Royal Manchester Children's Hospital, Manchester, UK) co-chairs of the European Society for Blood and Marrow Transplantation (EBMT) Trainee Committee. Together, they discuss their motivations ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.